The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide

The endothelial nitric oxide synthase Glu298Asp polymorphism has been suggested to play a role in the development of hypertension, atherosclerosis and coronary artery disease. To investigate functional differences between the various genotypes with respect to basal nitric oxide (NO) production, we e...

Full description

Saved in:
Bibliographic Details
Published inJournal of hypertension Vol. 20; no. 10; p. 2023
Main Authors Veldman, Bart A, Spiering, Wilko, Doevendans, Peter A, Vervoort, Gerald, Kroon, Abraham A, de Leeuw, Peter W, Smits, Paul
Format Journal Article
LanguageEnglish
Published England 01.10.2002
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The endothelial nitric oxide synthase Glu298Asp polymorphism has been suggested to play a role in the development of hypertension, atherosclerosis and coronary artery disease. To investigate functional differences between the various genotypes with respect to basal nitric oxide (NO) production, we estimated the response to endothelial NO synthase (ecNOS) inhibition by infusion of increasing doses of N(G)-monomethyl-L-arginine (L-NMMA) into the brachial artery during venous occlusion plethysmography. In 41 healthy subjects forearm blood flow responses to intra-arterial infusion of increasing doses of L-NMMA (0.05, 0.1 and 0.2 mg/min per dl) and norepinephrine (10, 20 and 40 ng/min per dl) were measured. The genotype of the ecNOS Glu298Asp polymorphism was assessed. Nineteen subjects had the Glu/Glu genotype, 19 subjects had the Glu/Asp genotype and three subjects had the Asp/Asp genotype. Groups were comparable concerning demographic, hemodynamic and possible confounding factors. Subjects with the Asp allele showed a reduced response to infusion of L-NMMA as compared to subjects with the Glu/Glu genotype (ANOVA, = 0.01). There was no significant difference in the response to infusion of the NO-independent vasoconstrictor, norepinephrine, between both groups. The ecNOS Glu298Asp polymorphism is associated with reduced basal NO production and might therefore have functional implications in the development of atherosclerosis or hypertension.
AbstractList The endothelial nitric oxide synthase Glu298Asp polymorphism has been suggested to play a role in the development of hypertension, atherosclerosis and coronary artery disease. To investigate functional differences between the various genotypes with respect to basal nitric oxide (NO) production, we estimated the response to endothelial NO synthase (ecNOS) inhibition by infusion of increasing doses of N(G)-monomethyl-L-arginine (L-NMMA) into the brachial artery during venous occlusion plethysmography. In 41 healthy subjects forearm blood flow responses to intra-arterial infusion of increasing doses of L-NMMA (0.05, 0.1 and 0.2 mg/min per dl) and norepinephrine (10, 20 and 40 ng/min per dl) were measured. The genotype of the ecNOS Glu298Asp polymorphism was assessed. Nineteen subjects had the Glu/Glu genotype, 19 subjects had the Glu/Asp genotype and three subjects had the Asp/Asp genotype. Groups were comparable concerning demographic, hemodynamic and possible confounding factors. Subjects with the Asp allele showed a reduced response to infusion of L-NMMA as compared to subjects with the Glu/Glu genotype (ANOVA, = 0.01). There was no significant difference in the response to infusion of the NO-independent vasoconstrictor, norepinephrine, between both groups. The ecNOS Glu298Asp polymorphism is associated with reduced basal NO production and might therefore have functional implications in the development of atherosclerosis or hypertension.
Author de Leeuw, Peter W
Smits, Paul
Vervoort, Gerald
Doevendans, Peter A
Veldman, Bart A
Spiering, Wilko
Kroon, Abraham A
Author_xml – sequence: 1
  givenname: Bart A
  surname: Veldman
  fullname: Veldman, Bart A
  organization: Department of Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
– sequence: 2
  givenname: Wilko
  surname: Spiering
  fullname: Spiering, Wilko
– sequence: 3
  givenname: Peter A
  surname: Doevendans
  fullname: Doevendans, Peter A
– sequence: 4
  givenname: Gerald
  surname: Vervoort
  fullname: Vervoort, Gerald
– sequence: 5
  givenname: Abraham A
  surname: Kroon
  fullname: Kroon, Abraham A
– sequence: 6
  givenname: Peter W
  surname: de Leeuw
  fullname: de Leeuw, Peter W
– sequence: 7
  givenname: Paul
  surname: Smits
  fullname: Smits, Paul
BackLink https://www.ncbi.nlm.nih.gov/pubmed/12359981$$D View this record in MEDLINE/PubMed
BookMark eNo1j19LwzAUxfMwcX_0K0i-QDW9adrkcQydwnAPzueRNDcu0ialacF9ezt0Fy6Hc8-PA3dJZiEGJITm7DFnqnpi0xSyggwYg_zismkBZmTBoORZyQXMyTKl7-ksVcVvyTwHLpSS-YKcDiek22YEJdepo11szm3su5NPLY2ODlP6vv-gnH5hQKoT1dTigH3rgw7DFTE6YeMnoOujHevBx3CJgh96X9P44y3ekRunm4T3_7oiny_Ph81rtttv3zbrXVYXAiCzmmNlOBhppDBOORCVFIV0kBeCGYuqlgBMaatLh4VlTpbW1OiM1oxzhBV5-OvtRtOiPXa9b3V_Pl5fhl-OWFpU
CitedBy_id crossref_primary_10_1007_s12031_007_9026_6
crossref_primary_10_1007_BF03256279
crossref_primary_10_1007_s10528_012_9545_x
crossref_primary_10_1016_j_ijrobp_2011_06_2012
crossref_primary_10_4238_2013_February_27_5
crossref_primary_10_1016_j_jchromb_2023_123627
crossref_primary_10_1161_01_RES_0000146513_73748_78
crossref_primary_10_1097_HJH_0b013e328317f215
crossref_primary_10_1097_MD_0000000000006642
crossref_primary_10_1111_j_1526_4610_2006_00614_x
crossref_primary_10_3109_00207454_2013_834336
crossref_primary_10_1016_j_mgene_2016_11_011
crossref_primary_10_1111_acps_12433
crossref_primary_10_1161_JAHA_120_020633
crossref_primary_10_1515_cclm_2013_0405
crossref_primary_10_1007_s10620_007_0002_3
crossref_primary_10_1586_eem_09_70
crossref_primary_10_1111_j_1468_2982_2009_01964_x
crossref_primary_10_1007_s10549_010_0833_z
crossref_primary_10_1159_000357442
crossref_primary_10_1016_j_envres_2006_01_001
crossref_primary_10_1089_dna_2005_24_218
crossref_primary_10_1158_1055_9965_EPI_07_0247
crossref_primary_10_1373_clinchem_2005_048850
crossref_primary_10_1002_jgm_2959
crossref_primary_10_1002_mrd_21210
crossref_primary_10_1093_molehr_gav008
crossref_primary_10_1097_01_hjh_0000182528_59687_d1
crossref_primary_10_1097_HJH_0b013e3283300506
crossref_primary_10_18632_oncotarget_8569
crossref_primary_10_1111_j_0197_3118_2006_05454_x
crossref_primary_10_2217_pgs_12_120
crossref_primary_10_1016_j_avsg_2010_09_004
crossref_primary_10_1111_crj_13228
crossref_primary_10_1007_s00701_007_1467_8
crossref_primary_10_1007_s10528_022_10208_5
crossref_primary_10_1161_01_HYP_0000147578_84729_ac
crossref_primary_10_1016_j_clinbiochem_2013_10_009
crossref_primary_10_1016_j_jcrc_2017_11_019
crossref_primary_10_1186_1471_2261_8_36
crossref_primary_10_1177_0961203309348980
crossref_primary_10_1016_j_metabol_2008_03_018
crossref_primary_10_1007_s00421_011_2042_9
crossref_primary_10_1111_j_1743_6109_2009_01353_x
crossref_primary_10_1111_j_1464_410X_2007_07110_x
crossref_primary_10_1111_j_1600_0897_2007_00551_x
crossref_primary_10_1371_journal_pone_0131741
crossref_primary_10_2337_dc06_1697
crossref_primary_10_7314_APJCP_2015_16_7_2929
crossref_primary_10_1016_j_bbrc_2007_07_008
crossref_primary_10_1186_1749_8090_8_199
crossref_primary_10_1097_MCA_0b013e328330d541
crossref_primary_10_1186_s12933_018_0742_8
crossref_primary_10_1038_oby_2010_224
crossref_primary_10_1177_0883073808330164
crossref_primary_10_1016_j_diff_2012_04_004
crossref_primary_10_14712_fb2011057050182
crossref_primary_10_1007_s13258_022_01246_9
crossref_primary_10_1016_j_atherosclerosis_2010_11_042
crossref_primary_10_1007_s00280_019_03933_z
crossref_primary_10_1038_jhh_2009_6
crossref_primary_10_1007_s10517_019_04652_4
crossref_primary_10_1161_01_RES_0000146279_11923_14
crossref_primary_10_1093_carcin_bgp028
crossref_primary_10_1007_s12017_011_8148_8
crossref_primary_10_1016_j_toxlet_2019_03_011
crossref_primary_10_1016_j_ejvs_2007_07_022
crossref_primary_10_1016_j_mgene_2019_100575
crossref_primary_10_31083_j_rcm2404119
crossref_primary_10_1016_j_gene_2018_03_021
crossref_primary_10_3390_v13081553
crossref_primary_10_1016_j_mgene_2016_03_004
crossref_primary_10_1080_00450618_2015_1112428
crossref_primary_10_1186_1475_2840_2_2
crossref_primary_10_1155_2009_302047
crossref_primary_10_1097_HJH_0b013e3281268548
crossref_primary_10_1161_CIRCULATIONAHA_110_978528
crossref_primary_10_1038_s41366_018_0124_z
crossref_primary_10_2337_diabetes_54_9_2795
crossref_primary_10_1002_iub_1513
crossref_primary_10_1016_j_trsl_2012_05_004
crossref_primary_10_1111_bju_13468
crossref_primary_10_1007_s00296_006_0199_z
crossref_primary_10_1371_journal_pone_0012402
crossref_primary_10_2217_pgs_2016_0118
crossref_primary_10_1002_jcla_20085
crossref_primary_10_5045_br_2022_2022014
crossref_primary_10_3389_fgene_2022_887415
crossref_primary_10_1089_ham_2008_1089
crossref_primary_10_3390_w16162266
crossref_primary_10_1016_j_niox_2021_03_004
crossref_primary_10_1016_S0955_2863_03_00032_9
crossref_primary_10_1016_j_hrthm_2006_08_001
crossref_primary_10_1016_j_gene_2015_05_042
crossref_primary_10_1111_j_1464_410X_2010_09755_x
crossref_primary_10_1007_s13258_010_0018_5
crossref_primary_10_1186_1471_2350_9_43
crossref_primary_10_1002_art_11307
crossref_primary_10_1016_j_actatropica_2018_11_015
crossref_primary_10_1016_j_cyto_2023_156415
crossref_primary_10_1007_s11033_011_1092_8
crossref_primary_10_1093_carcin_bgp053
crossref_primary_10_1002_ajmg_b_30569
crossref_primary_10_1016_j_gene_2012_10_027
crossref_primary_10_1016_j_jvs_2010_02_021
crossref_primary_10_1177_108925320300700105
crossref_primary_10_1007_s00228_012_1280_z
crossref_primary_10_1007_s00418_004_0675_z
crossref_primary_10_1016_j_jacc_2009_04_014
crossref_primary_10_1161_01_STR_0000177867_39769_cb
crossref_primary_10_1007_s11033_008_9348_7
crossref_primary_10_1042_CS20050090
crossref_primary_10_1186_1471_2350_11_167
crossref_primary_10_1002_jcb_27733
crossref_primary_10_1161_01_HYP_0000141440_02210_da
crossref_primary_10_3171_2011_2_FOCUS10227
crossref_primary_10_1111_j_1524_6175_2006_06042_x
crossref_primary_10_3109_10715762_2013_793319
crossref_primary_10_1016_j_ahj_2004_05_059
crossref_primary_10_1016_j_gene_2012_10_032
crossref_primary_10_1111_j_1526_4610_2007_00898_x
crossref_primary_10_1097_HJH_0b013e328334f55c
crossref_primary_10_1007_s13277_014_2097_4
crossref_primary_10_1681_ASN_2009070721
crossref_primary_10_1007_s12032_010_9647_4
crossref_primary_10_1016_j_yexmp_2010_08_009
crossref_primary_10_4143_crt_2015_360
crossref_primary_10_1155_2016_4985063
crossref_primary_10_3349_ymj_2015_56_5_1244
crossref_primary_10_1016_j_atherosclerosis_2010_06_010
crossref_primary_10_1038_ajh_2009_38
crossref_primary_10_1038_s41598_023_39576_7
crossref_primary_10_1111_jsm_12896
crossref_primary_10_1016_j_acvfr_2012_03_017
crossref_primary_10_1038_sj_jhh_1002169
crossref_primary_10_1016_j_clnu_2010_08_006
crossref_primary_10_1016_j_jvs_2005_05_044
crossref_primary_10_1515_CCLM_2008_271
crossref_primary_10_1136_postgradmedj_2019_136396
crossref_primary_10_1097_01_hjh_0000242407_58159_87
crossref_primary_10_1371_journal_pone_0142872
crossref_primary_10_1016_j_redox_2013_12_001
crossref_primary_10_1007_s10549_010_0800_8
crossref_primary_10_1016_j_anorl_2015_10_004
crossref_primary_10_1038_jhh_2008_62
crossref_primary_10_1038_srep42541
crossref_primary_10_1016_j_metabol_2006_04_012
crossref_primary_10_1007_s11010_017_3135_5
crossref_primary_10_1111_iji_12176
crossref_primary_10_1159_000341487
crossref_primary_10_1016_j_placenta_2025_01_005
crossref_primary_10_1161_STROKEAHA_107_493593
crossref_primary_10_1016_j_humgen_2023_201184
crossref_primary_10_12688_f1000research_22989_2
crossref_primary_10_12688_f1000research_22989_1
crossref_primary_10_1016_j_radonc_2011_12_002
crossref_primary_10_1007_s10545_008_0920_z
crossref_primary_10_1016_j_atherosclerosis_2014_05_936
crossref_primary_10_1016_j_gene_2013_02_001
crossref_primary_10_1016_j_cyto_2017_05_010
crossref_primary_10_1097_00041433_200404000_00006
crossref_primary_10_1093_humupd_dms060
crossref_primary_10_1016_j_humimm_2008_03_003
crossref_primary_10_1097_01_hjh_0000163144_74588_ad
crossref_primary_10_1038_srep13598
crossref_primary_10_1016_j_neurobiolaging_2010_06_012
crossref_primary_10_1002_jgm_3323
crossref_primary_10_1007_s11010_018_3470_1
crossref_primary_10_1016_j_nut_2014_08_009
crossref_primary_10_1016_j_niox_2018_06_005
crossref_primary_10_1016_j_ejvs_2004_02_008
crossref_primary_10_1016_j_aforl_2016_04_001
crossref_primary_10_1016_j_ahj_2003_10_032
crossref_primary_10_1111_j_1468_1331_2008_02335_x
crossref_primary_10_22627_2072_8107_2025_24_1_51_55
crossref_primary_10_1177_0003319709339589
crossref_primary_10_1007_s11010_008_9874_6
crossref_primary_10_1038_jhh_2008_34
crossref_primary_10_1177_1470320309104877
crossref_primary_10_1155_2020_1305413
crossref_primary_10_1097_SHK_0b013e318188e58e
crossref_primary_10_1177_2045894018773049
crossref_primary_10_3109_09537100903337401
crossref_primary_10_1016_j_semnephrol_2012_02_006
crossref_primary_10_15171_ijb_1307
crossref_primary_10_1371_journal_pone_0087196
crossref_primary_10_1161_01_HYP_0000185462_08685_da
crossref_primary_10_1007_s00404_013_2991_9
crossref_primary_10_1016_j_neurobiolaging_2004_07_003
crossref_primary_10_1016_j_siny_2018_08_006
crossref_primary_10_1371_journal_pone_0129372
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1097/00004872-200210000-00022
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 12359981
Genre Journal Article
Comparative Study
GroupedDBID ---
.-D
.55
.GJ
.XZ
.Z2
01R
0R~
1J1
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAUEB
AAWTL
AAXQO
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABVCZ
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACIJW
ACILI
ACLDA
ACWDW
ACWRI
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFDTB
AFEXH
AFFNX
AFSOK
AFUWQ
AGINI
AHOMT
AHQNM
AHRYX
AHVBC
AI.
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BOYCO
BQLVK
BS7
C45
CAG
CGR
COF
CS3
CUY
CVF
DIWNM
DU5
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JF9
JG8
JK3
JK8
K8S
KD2
KMI
L-C
L7B
N9A
NPM
N~7
N~B
N~M
O9-
OAG
OAH
OCUKA
ODA
ODMTH
OHYEH
OJAPA
OL1
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VH1
VVN
W3M
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YYP
ZFV
ZGI
ZXP
ZZMQN
ID FETCH-LOGICAL-c4522-da3e7b32b8b85bf9f2578548f21450bde9c82209ada6fe4d0f86dbcefbaa033e2
ISSN 0263-6352
IngestDate Wed Feb 19 02:35:36 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4522-da3e7b32b8b85bf9f2578548f21450bde9c82209ada6fe4d0f86dbcefbaa033e2
PMID 12359981
ParticipantIDs pubmed_primary_12359981
PublicationCentury 2000
PublicationDate 2002-October
PublicationDateYYYYMMDD 2002-10-01
PublicationDate_xml – month: 10
  year: 2002
  text: 2002-October
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of hypertension
PublicationTitleAlternate J Hypertens
PublicationYear 2002
SSID ssj0008973
Score 2.1872644
Snippet The endothelial nitric oxide synthase Glu298Asp polymorphism has been suggested to play a role in the development of hypertension, atherosclerosis and coronary...
SourceID pubmed
SourceType Index Database
StartPage 2023
SubjectTerms Adolescent
Adult
Alleles
Dipeptides - genetics
Dose-Response Relationship, Drug
Enzyme Inhibitors - administration & dosage
Female
Forearm - blood supply
Genotype
Humans
Infusions, Intra-Arterial
Male
Nitric Oxide - genetics
Nitric Oxide - metabolism
Nitric Oxide Synthase - drug effects
Nitric Oxide Synthase - genetics
Nitric Oxide Synthase Type III
Norepinephrine - administration & dosage
omega-N-Methylarginine - administration & dosage
Polymorphism, Genetic - genetics
Reference Values
Regional Blood Flow - drug effects
Regional Blood Flow - physiology
Vasoconstrictor Agents - administration & dosage
Title The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide
URI https://www.ncbi.nlm.nih.gov/pubmed/12359981
Volume 20
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELUKSIgLYt-RD9xQULCb7QiIRUiUA6XqDdmxLRDQVCwS4mP4VmZsp0lLEcslquI0SjzPk5nxmxlCdhIeJYZFKuA6SYIm1vsUmeEBSxWXkvGmSTAb-aIVn103z7tRt9H4qLGWXl_kXv4-Nq_kP1KFcyBXzJL9g2QHN4UT8BvkC0eQMBx_L-OHV5alB8997LcAjjzMG_a98Fv_rcurXY5tkjU2lBG7qmK_lJfgd8zamn1X_NVbkLDUkWRfvN2pYbZQZcHegg_7ZBnw1V5-Rz8oH1Q9hCeuQqW4Pf_kG6iAKrovBiZ0gUWklDfoLV-4-lcHVFnhm92f2vDZUJiCDQhvpTZjMQ_AuhlSvSysQyysK9LQpSF_0fCucrB1bdKEBZZjEvr0eJfhXBN8_9FKHvOBwa3c_3l0pPZ2OTRBJsALwbaqGAvy3_k0c_yF8sU8T6wsCTru8bBErb_liBtjzZn2HJn1UqQHDlTzpKF7C2T6wjMtFsktYIsOsEXr2KKFoQAcCtiinCK2qHimgtawVV5SYotW2MIhhy1qsbVErk-O20dnge_KEeRYfT9QApa15EymMo2kyQwqffB7Dda8D6XSWQ5GZ5gJJWKjmyo0aaxkro0UIuRcs2Uy2St6epXQWOZRwg3nGVjlUaRFqjlYxMIksWHSRGtkxc3RTd-VXrkpZ2_925ENMlPBb5NMGVjregsMxxe5beX3Cc8faBs
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Glu298Asp+polymorphism+of+the+NOS+3+gene+as+a+determinant+of+the+baseline+production+of+nitric+oxide&rft.jtitle=Journal+of+hypertension&rft.au=Veldman%2C+Bart+A&rft.au=Spiering%2C+Wilko&rft.au=Doevendans%2C+Peter+A&rft.au=Vervoort%2C+Gerald&rft.date=2002-10-01&rft.issn=0263-6352&rft.volume=20&rft.issue=10&rft.spage=2023&rft_id=info:doi/10.1097%2F00004872-200210000-00022&rft_id=info%3Apmid%2F12359981&rft_id=info%3Apmid%2F12359981&rft.externalDocID=12359981
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0263-6352&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0263-6352&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0263-6352&client=summon